Sono-Tek Corporation (SOTK) reported results of its annual meeting of shareholders held on August 20, 2026. Shareholders elected three directors: Eric Haskell (4,820,731 votes for, 323,232 against, 6,483,666 broker non-votes), Adeniyi Lawal (5,009,487 for, 134,476 against, 6,483,666 broker non-votes), and Carol O’Donnell (4,837,468 for, 306,495 against, 6,483,666 broker non-votes). Other directors whose terms run through August 2027 continue to serve on the board. Shareholders also voted on another matter that received 11,611,748 votes for, 13,467 against and 2,414 abstentions, with no broker non-votes. Sono-Tek furnished, but did not file, an investor presentation from the annual meeting as Exhibit 99.1 under Items 2.02 and 7.01.
Sono Tek Corp CFO Stephen James Bagley sold 8,346 shares of SonoTek Common Stock on 2026-07-30 in an open market or private transaction at a weighted average price of $5.13 per share, with prices ranging from $5.10 to $5.18. After the sale, he directly holds 21,254 shares, and the filing indicates the trades were not made under a Rule 10b5-1 plan.
Sono-Tek Corp CFO Stephen James Bagley sold 1,200 shares of SonoTek Common Stock on July 27, 2026, in an open-market or private transaction at a weighted average price of $5.075 per share, with prices ranging from $5.10 to $5.12, and now directly holds 29,600 shares.
Sono-Tek Corp CFO Stephen James Bagley sold 3,454 shares of Common Stock on July 23, 2026 at a weighted average price of $5.431 per share, in multiple transactions between $5.40 and $5.46. After this sale, he directly owns 30,800 shares.
SONO TEK CORP director Christopher L. Coccio sold 17,000 shares of SOTK Common Stock on July 21, 2026 in an open-market or private transaction. The shares were sold at a weighted average price of $5.375 per share, with individual sale prices between $5.37 and $5.44. After this sale, he directly owns 292,447 shares. No Rule 10b5-1 trading plan was indicated for this transaction.
Sono-Tek Corporation asks shareholders at its August 20, 2026 annual meeting to elect three directors—Eric Haskell, Adeniyi Lawal and Carol O’Donnell—to terms ending at the 2028 meeting, and to ratify CBIZ CPAs as independent auditors for the fiscal year ending February 28, 2027.
Common shares outstanding were 15,716,723 as of July 20, 2026. The seven-member Board includes five independent directors and operates Audit, Compensation and Nominating Committees. Fiscal 2026 total compensation was $408,100 for CEO R. Stephen Harshbarger, $270,700 for CFO Stephen Bagley and $300,000 for COO Christopher Cichetti. Net income was $1,805,681. A holder group led by Emancipation Management owns 5,472,052 shares, or 34.82% of common stock.
A stockholder of SonoTek Corporation filed to sell 17,000 shares of common stock through Merrill Lynch on Nasdaq. The proposed sale has an aggregate market value of $94,520 and relates to shares acquired via stock option exercises dated January 1, 2004. SonoTek reports 15,716,723 shares of common stock outstanding.
Sono-Tek Corporation reported higher results for the first quarter of fiscal 2027. Net sales rose to $5,661,000 from $5,133,000, a 10% increase, driven largely by strong medical market shipments, including specialty stent and drug-eluting balloon coating systems. Gross profit improved to $3,214,000, with margin expanding to 57% from 52%, helped by a favorable product mix and more U.S.-based sales.
Net income increased to $741,168, or $0.05 per diluted share, compared with $484,985, or $0.03 per share, a year earlier. Medical market revenue grew sharply while alternative energy sales declined after a large prior-year solar order. Cash, cash equivalents and marketable securities totaled $16,652,000 with no outstanding debt, and combined equipment and service-related backlog was $7.73 million, slightly above the prior year. About 38% of sales came from customers outside the United States and Canada.